Search results for Trenibotulinumtoxine

Allergan Aesthetics Receives Positive CHMP Opinion for TrenibotulinumtoxinE for Glabellar Lines

The botulinum neurotoxin type E candidate is designed for a faster onset and shorter duration of effect than currently available neurotoxin treatments.

FDA Issues Complete Response Letter for AbbVie’s Fast-Acting Toxin Application

Agency requests additional manufacturing information and does not cite safety or efficacy concerns or require new clinical studies.

<![CDATA[FDA Issues CRL to AbbVie for TrenibotulinumtoxinE’s Biologics License Application ]]>

Ipsen unveils data for Botox rival that drove long-acting anti-wrinkle jab into phase 3

Ipsen has shared phase 2 data on its long-acting neurotoxin, reporting an increase in the proportion of people with significant improvements in frown lines 24 weeks after treatment...

China Approves First Recombinant Botulinum Toxin for Glabellar Lines

The neurotoxin, developed by Claruvis Pharmaceutical, uses a precision-engineered recombinant manufacturing process for botulinum toxin type A.

Ipsen unveils corabotase, a first-in-class recombinant neuroinhibitor, RNIâ„¢, at the SCALE Symposium

Corabotase is the first investigational molecule in a newly designated class of recombinant neuroinhibitors, RNITM, as recognized by the WHO and USAN  Phase II data in glabell...

Ipsen presents first-in-class late-breaking Phase II corabotase data in glabellar lines showing sustained duration of ef...

Patients treated with corabotase showed a rapid onset of action of 0.84 days and peak effect statistically superior to placebo At Week 24, 60.8% of patients treated with corabotase...